MedTrace Logo

ABT-510 in Treating Patients With Metastatic Melanoma

NCT00602199 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2011-05-16

No results posted yet for this study

Summary

RATIONALE: ABT-510 may stop the growth of melanoma by blocking blood flow to the tumor.

PURPOSE: This phase II trial is studying how well giving ABT-510 works in treating patients with metastatic melanoma.

Conditions

  • Melanoma (Skin)

Interventions

DRUG

ABT-510

OTHER

immunoenzyme technique

OTHER

immunohistochemistry staining method

OTHER

laboratory biomarker analysis

OTHER

pharmacological study

PROCEDURE

biopsy

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Svetomir Markovic, MD, PhD · Mayo Clinic

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-30
Primary Completion
2005-06-30
Completion
2005-06-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00602199 on ClinicalTrials.gov